Acessa Health said today that it closed the bankruptcy buyout of Halt Medical and promptly raised a Series A round worth $30 million. The Acessa device is designed to treat uterine fibroids using radiofrequency ablation. Its successor namesake emerged after a Delaware federal bankruptcy judge earlier this month approved the bankruptcy sale, which was designed to keep the […]
Court approves Halt Medical’s bankruptcy sale
A Delaware federal bankruptcy judge yesterday approved a bankruptcy sale of Halt Medical designed to keep its Acessa uterine fibroid treatment on the market. The Brentwood, Calif.-based women’s health company filed for Chapter 11 bankruptcy protection in April, citing assets valued at $2.2 million as of March 31 but liabilities of about $156.3 million, including a $497,000 severance payment to […]
Halt Medical finds backer for Chapter 11 bankruptcy reorganization
Halt Medical said yesterday that it’s reorganizing under a Chapter 11 bankruptcy, via an acquirer that’s floating a $4 million bridge loan to sustain the women’s health company’s operations during the sale process. The company owes its top 20 creditors a total of nearly $1.3 million, including a $497,000 severance payment to former chief executive Jeffrey Cohen, according to […]
Halt Medical wins Medicaid coverage for Acessa treatment in 5 states
Halt Medical said today it won coverage for its Acessa System from Medicaid in Texas, Ohio, Michigan, Indiana and Washington D.C. The Acessa system uses radiofrequency ablation guided by ultrasound to remove fibroids, which are benign, non-cancerous tumors that occur in women’s uteri, often during childbearing years, Brentwood, Calif.-based Halt Medical said. The company said the coverage […]
Women in medtech: Making gains but not there yet
Sarah Faulkner/Associate Editor When IBM Watson Health general manager Deborah DiSanzo, a 30-year medtech veteran, began as a project manager at Apollo Computer, there were plenty of women working beside her. Three decades later, DiSanzo said, “I can now point to one woman who’s still in medtech from that.” The anecdote illustrates the continuing gender […]
Halt Medical touts BCBS reimbursement win in South Carolina
Halt Medical said today that it won coverage from Blue Cross Blue Shield of South Carolina for procedures using its Acessa System to remove fibroids. Acessa uses radiofrequency ablation guided by ultrasound to remove fibroids, which are benign, non-cancerous tumors that occur in women’s uteri, often during childbearing years, Halt Medical said. The Brentwood, Calif.-based company […]
GI Dynamics taps medtech vet Schorer for CEO | Personnel Moves March 25, 2016
GI Dynamics taps medtech vet Schorer for CEO Troubled GI Dynamics (ASX:GID) said this week that it named a veteran medical device executive, Scott Schorer, to be its new president & CEO effective immediately. Schorer spent the last 6 years as a consultant, advising and helping run companies including stealthy Auris Robotics and Neograft Technologies, and […]
Halt Medical wins reimbursement for Acessa fibroid treatment
Halt Medical said yesterday that its Acessa treatment for symptomatic firbroids is now covered by Blue Cross Blue Shield of Michigan. Acessa uses radiofrequency ablation guided by ultrasound to remove fibroids, which are benign, non-cancerous tumors that occur in women’s uteri, often during childbearing years, Halt Medical said. “Millions of women suffer from heavy bleeding, pain […]
Stealthy Auris Surgical Robotics raises more than $34 million in an equity round | Medtech funding stories for the week of Mar. 31, 2014
Halt Medical raises $92.8M ahead of U.S. launch of uterine fibroid treatment
California women’s health company Halt Medical is raising capital ahead of a major commercial bid for its Acessa radiofrequency-based uterine fibroid treatment.
Women’s health: Halt Medical lands Mexican win for uterine fibroid treatment
Women’s health devices maker Halt Medical touted a win from Mexican healthcare regulators who granted registration for the Acessa System for treating uterine fibroids.
The Acessa technology represents a major shift in treatment of uterine fibroids, the company has said. Fibroids are the leading global cause of hysterectomy procedures, according to the Centers for Disease Control & Prevention.
MassDevice Network
@MassDevice
LinkedIn
Google+